Lupus anticoagulant activity and thrombosis post COVID-19 vaccination.


Journal

Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis
ISSN: 1473-5733
Titre abrégé: Blood Coagul Fibrinolysis
Pays: England
ID NLM: 9102551

Informations de publication

Date de publication:
01 Jan 2023
Historique:
pubmed: 11 8 2022
medline: 7 1 2023
entrez: 10 8 2022
Statut: ppublish

Résumé

Some reports have discussed the development of a new entity called vaccine-induced immune thrombotic thrombocytopenia after COVID-19 vaccination. In this case series, we are describing four patients who have developed lupus anticoagulant-associated venous thromboembolism after Pfizer mRNA COVID-19 vaccination. All were COVID-19 negative on admission. Three had developed thrombosis after the first dose and one after the second dose of vaccination. All of them had venous thrombosis. Three patients developed thrombosis 2 weeks after vaccination and the fourth patient had developed thrombosis after 3 weeks of vaccination. None of the patients had thrombocytopenia on or during admission as seen in the case of vaccine-induced immune thrombotic thrombocytopenia. All patients had positive lupus anticoagulant and negative anticardiolipin antibodies and antibeta2 glycoprotein I. All of them were stable on discharge and were treated with low molecular weight heparin followed by warfarin. We suggest the presence of a possible link between the development of antiphospholipid antibodies and COVID-19 vaccine that requires further assessment.

Identifiants

pubmed: 35946452
doi: 10.1097/MBC.0000000000001161
pii: 00001721-202301000-00011
doi:

Substances chimiques

Lupus Coagulation Inhibitor 0
COVID-19 Vaccines 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

75-78

Informations de copyright

Copyright © 2022 Wolters Kluwer Health, Inc. All rights reserved.

Références

Al-Ahmad M, Al-Rasheed M, Shalaby NAB. Acquired thrombotic thrombocytopenic purpura with possible association with AstraZeneca-Oxford COVID-19 vaccine. EJHaem 2021; 2:534–536.
Behlivani E, Tragiannidis A, Hatzipantelis E, Panagopoulou P. Immune thrombocytopenia secondary to COVID-19 infection: report of two cases. Pediatr Blood Cancer 2021; 68:e29175.
Radwi M, Farsi S. A case report of acquired hemophilia following COVID-19 vaccine. J Thromb Haemost 2021; 19:1515–1518.
Franchini M, Liumbruno GM, Pezzo M. COVID-19 vaccine-associated immune thrombosis and thrombocytopenia (VITT): diagnostic and therapeutic recommendations for a new syndrome. Eur J Haematol 2021; 107:173–180.
McGonagle D, De Marco G, Bridgewood C. Mechanisms of immunothrombosis in vaccine-induced thrombotic thrombocytopenia (VITT) compared to natural SARS-CoV-2 infection. J Autoimmun 2021; 121:102662.
Segal Y, Shoenfeld Y. Vaccine-induced autoimmunity: the role of molecular mimicry and immune crossreaction. Cell Mol Immunol 2018; 15:586–594.
Talotta R. Do COVID-19 RNA-based vaccines put at risk of immune-mediated diseases? In reply to “potential antigenic cross-reactivity between SARS-CoV-2 and human tissue with a possible link to an increase in autoimmune diseases”. Clin Immunol 2021; 224:108665.
Duarte-Garcia A, Pham MM, Crowson CS, Amin S, Moder KG, Pruthi RK, et al. The epidemiology of antiphospholipid syndrome: a population-based study. Arthritis Rheumatol 2019; 71:1545–1552.
Chighizola CB, Raschi E, Banzato A, Borghi MO, Pengo V, Meroni PL. The challenges of lupus anticoagulants. Expert Rev Hematol 2016; 9:389–400.
Yin D, de Groot PG, Ninivaggi M, Devreese KMJ, de Laat B. Clinical relevance of isolated lupus anticoagulant positivity in patients with thrombotic antiphospholipid syndrome. Thromb Haemost 2021; 121:1220–1227.
Talotta R, Robertson ES. Antiphospholipid antibodies and risk of post-COVID-19 vaccination thrombophilia: the straw that breaks the camel's back? Cytokine Growth Factor Rev 2021; 60:52–60.
Sciascia S, Costanzo P, Radin M, Schreiber K, Pini M, Vaccarino A, et al. Safety and tolerability of mRNA COVID-19 vaccines in people with antiphospholipid antibodies. Lancet Rheumatol 2021; 3:e832.
Alam W. COVID-19 vaccine-induced immune thrombotic thrombocytopenia: a review of the potential mechanisms and proposed management. Sci Prog 2021; 104:368504211025927.
Aleem A, Nadeem AJ. Coronavirus (COVID-19) vaccine-induced immune thrombotic thrombocytopenia (VITT). Treasure Island (FL): StatPearls; 2021.
Arepally GM, Ortel TL. Vaccine-induced immune thrombotic thrombocytopenia (VITT): what we know and don’t know. Blood 2021; 138:293–298.
Simpson CR, Shi T, Vasileiou E, Katikireddi SV, Kerr S, Moore E, et al. First-dose ChAdOx1 and BNT162b2 COVID-19 vaccines and thrombocytopenic, thromboembolic and hemorrhagic events in Scotland. Nat Med 2021; 27:1290–1297.

Auteurs

Mona Al-Ahmad (M)

Microbiology Department, Faculty of Medicine, Kuwait University.
Al Rashed Allergy Centre, Ministry of Health.

Mona Al Rasheed (M)

Hematology Unit, Department of Medicine, Al Adnan Hospital, Ministry of Health, Kuwait City, Kuwait.

Lulwa Altourah (L)

Hematology Unit, Department of Medicine, Al Adnan Hospital, Ministry of Health, Kuwait City, Kuwait.

Tito Rodriguez-Bouza (T)

Hospital Quirón Palmaplanas, Centro de Patología Alérgica, Balearic Islands, Spain.

Neveen Shalaby (N)

Hematology Unit, Department of Medicine, Al Adnan Hospital, Ministry of Health, Kuwait City, Kuwait.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH